According to the Market Statsville Group (MSG), the global corneal endothelial cell transplant market size is expected to grow from USD 466.37 million in 2022 to USD 956.18 million by 2033, at a CAGR of 6.3% from 2023 to 2033.
In EK, a new method of corneal transplantation, a healthy new endothelium is transplanted on a thin layer of donor corneal tissue which is floated into place and adheres without sutures. The eye wall is left intact. This helps to preserve a normal corneal shape, normal strength and a normal focusing power for the eye. In recent years, the prevalence of ocular illnesses such as cataract and glaucoma has increased dramatically. Such an increase in ophthalmic diseases has created a high need for effective diagnosis to design perfect treatment and correction. This is expected to propel growth of the artificial cornea and corneal endothelial cell transplant market. Moreover, the surge in government initiatives to control visual impairment also boosted the market growth over the forecast period. On the other hand, Technological advancements in ophthalmic lasers, such as development of femtosecond lasers, have reduced surgery time and improved procedural outcomes and convenience. However, the high cost of these instruments is expected to restrain their growth. Whereas an increase in technological advancements in the field of cornea will create huge opportunities for the new player and existing player to grow in the market over the period.
Corneal endothelial transplantation, also known as DSEK (Descemet's Stripping Endothelial Keratoplasty) or DSAEK (Descemet's Stripping Automated Endothelial Keratoplasty), is the recommended treatment option for the majority of persons with substantial corneal endothelial failure. At the very front of the eye, there is a clear window called the cornea. A thin layer of cells-endothelium covers the inner layer of the cornea. The endothelium's role is to maintain the cornea clean by pumping water out of it. The endothelial cells are like brain cells, and bodies cannot make new ones if they wear out or are damaged and the cornea becomes cloudy and swollen (oedema) which makes the vision blurry. This is most commonly caused by a condition called Fuchs’ corneal dystrophy, which is accelerated ageing and loss of endothelial cells.
DSEK surgery has revolutionized corneal transplantation for corneal endothelial dysfunction such as Fuchs’ dystrophy. It is much safer with much faster visual recovery and improved visual quality. It is still a transplant surgery however, so significant complications are possible, and lifelong treatment with eye drops and regular eye checks are usually required afterwards. For most people with significant visual symptoms from corneal endothelial dysfunction, though the results are now excellent and because of this many people are having their surgery much earlier than was recommended previously.
COVID-19 was spreading rapidly throughout the world. Concerns about the asymptomatic transmission of COVID-19, the lack of adequate testing, the potential overwhelming of our healthcare system, and the need to conserve essential medical supplies led to drastic shutdown measures in the US and throughout the world. The EBAA COVID-19 screening recommendations continued to evolve to keep pace with the rapidly changing nature of the pandemic. With so many unknowns, the donor screening recommendations were extremely conservative, resulting in significant donor deferrals. Fortunately, this decrease in ocular donors corresponded with a recommendation from the American Academy of Ophthalmology on March 18, 2020, for immediate cessation of any ophthalmic treatment other than urgent or emergent care. In the matter of a week, ophthalmic care in the US virtually grounded to a halt, including elective corneal transplantation. In a survey conducted by the EBAA of the US eye banks, the volume of tissue distributed for corneal transplantation procedures declined to approximately 6% and 7% of the normal volume for domestic surgeries and 4% and 1% of the normal volume for international surgeries in March (with 50 eye banks reporting) and April (34 eye banks reporting), respectively (K. Corcoran, personal communication, July 31, 2020).
Prevalence of ophthalmic diseases such as glaucoma and cataract has witnessed a dramatic increase in recent years. Such an increase in ophthalmic diseases has created high need for effective diagnosis to design perfect treatment and correction. This is expected to propel growth of the artificial cornea and corneal implant market. Such an increase in ophthalmic diseases has created high need for effective diagnosis to design perfect treatment and correction. This is expected to propel growth of the artificial cornea and corneal implant market.
Major reasons for corneal disorders in elderly population include corneal degenerations, trauma-induced infectious keratitis, and trachomatous keratopathy. Hence, to prevent corneal blindness, constant assessment of burden of corneal blindness with a periodic review is necessary. Such a scenario results in rise in demand for corneal implants, including artificial implants to treat corneal diseases. Cataract is a major concern globally, which is currently the leading cause of blindness as per the World Health Organization followed by glaucoma and accompanied with other leading causes, which result into blindness.
Technological advancements in ophthalmic lasers, such as the development of femtosecond lasers, have reduced surgery time and improved procedural outcomes and convenience. However, the high cost of these instruments is expected to restrain their growth. According to a study conducted by the Singapore Eye Research Institute (SERI), cost of a femtosecond laser was $400,000–$550,000. This affects their adoption among end users, as it is difficult to estimate the number of patients choosing femtosecond laser therapy over conventional methods and whether the number of patients choosing the therapy can cover installation cost of the laser. Similarly, the cost of an OCT (optical coherence tomography) ranges from $70,000 to $120,000, and the cost of new fundus machines ranges from $15,000 to $60,000. The cost of laser eye surgeries depends on various factors, such as amount of correction needed, type of technology used, and experience and reputation of the surgeon. Furthermore, LASIK (commonly referred to as laser eye surgery or laser vision correction) prices increased slightly in 2019, owing to advancements in laser technologies. The average price ranges between $1,000 and $3,000 per eye. In 2019, the average cost of a LASIK procedure using blade method was $1,500 per eye, whereas average cost of bladeless custom wave front LASIK procedure was $ 2,000 per eye. Moreover, the cost of laser eye surgery varies from region to region. For instance, in the US, average cost of these surgeries ranged from $1,500–2,300 per eye; in the UK, average cost ranged from $1,280–3,800 per eye; and in Australia, the cost ranged from $ 1,500–4,300 per eye.
According to the cornea research foundation of America, it has been estimated that up to 10 million people across the globe will suffer from corneal blindness. Only 100,000 corneal transplants are performed each and every year across the globe due to lack of access to donor tissues, which has been described as an international crisis for public health. In addition, one of the advantages of artificial cornea is that it can help to restore vision in patient’s eyes who are not good a candidate for a living corneal transplant from a human donor. For instance, Corneat vision launched CorNeat KPro (synthetic cornea), which provides a long-lasting medical solution for pathology, injury and corneal blindness. The CorNeat KPro implant is a patented technique that synthetic cornea utilizing advanced cell technology to integrate artificial optics within resident ocular tissue. It is produced using nanoscale chemical engineering, which stimulates cellular growth. This further propels key manufacturers to introduce advanced and novel artificial cornea in the market. Hence, introduction of such advanced technologies is projected to boost the market growth for the forecast period.
The study categorizes the corneal endothelial cell transplant market based on technique, indication, end-user area at the regional and global levels.
Based on the technique, the market is split into descemet membrane endothelial keratoplasty (dmek), deep lamellar endothelial keratoplasty (dlek), descemet stripping endothelial keratoplasty (dsek), descemet stripping automated endothelial keratoplasty (dsaek), pre-descemet endothelial keratoplasty (pdek), descemetorhexis without endothelial keratoplasty (dwek), descemet stripping only (dso) and descemet membrane endothelial transfer (dmet). The descemet membrane endothelial keratoplasty (dmek) segment is expected to dominate the market share in 2022 in the global corneal endothelial cell transplant market. In Descemet’s stripping endothelial keratoplasty (DSEK), the patient’s Descemet membrane is peeled off, using specially designed strippers and replaced with a partial thickness graft a transplanted disc of Posterior Stroma, Descemet and Endothelium (10-30 % of the inner donor cornea). This surgery is performed throughout a small incision, requiring that the graft be folded or rolled to get it into the eye. It is then held into position with an air bubble for a period of time, after which (most of the time) it adheres. Due to its small incision with few sutures, faster visual recovery than after full thickness corneal transplantation, and minimal change in astigmatism or post-operative refraction, this segment resister higher growth over the forecast period.
Based on the regions, the global corneal endothelial cell transplantmarket has been segmented across Europe, North America, the Middle East & Africa, Asia-Pacific and South America. North America dominated the global corneal endothelial cell transplant market in 2022. It is due to the growing government initiative in the health care industry and technology advancement is expected to grow in this region. For instance, The United States collaborates with different countries to improve health care outcomes through strengthened health care systems, with a particular emphasis on women's, adolescent girls', newborns', and children's health, through programmers that address infectious disease, nutrition, maternal and child health, family planning, safe water, sanitation, and hygiene. This government initiative boosts the market for the period.
The corneal endothelial cell transplant market is significant competitors and extremely cutthroat in the sector are using strategies including product launches, partnerships, acquisitions, agreements, and growth to enhance their market positions. Most sector businesses focus on increasing their operations worldwide and cultivating long-lasting partnerships.
Frequently Asked Questions
Want to Review Complete Market Research Report
Budget constraints? Get in touch with us for special pricing
Request for Special PricingCustomize this Report
Related Reports
Metagenomics Sequencing Market 2021: Industry Size, Regions, Emerging Trends, Growth Insights, Opportunities, and Forecast By 2027
Mar 2024Medical Cannabis Oil Market 2021: Industry Size, Regions, Emerging Trends, Growth Insights, Development Scenario, Opportunities, and Forecast By 2027
Mar 2024Novel Vaccine Delivery System Market 2021: Industry Size, Regions, Emerging Trends, Growth Insights, Opportunities, and Forecast By 2027
Mar 2024Lysosomal Storage Disease Treatment Market 2021: Industry Size, Regions, Emerging Trends, Growth Insights, Development Scenario, Opportunities, and Forecast By 2027
Mar 2024Single-Use Bioprocessing Market 2022: Industry Size, Emerging Trends, Regions, Growth Insights, Opportunities, and Forecast By 2033
Mar 2024